The VT IDeA Retreat is being organized by the Vermont Biomedical Research Network. We encourage your participation in this exciting program that will bring together faculty from across Vermont to strengthen our biomedical research infrastructure - a key goal of NIGMS’ IDeA program.

Despite a record number of over 400 million cases in 2019, vaccine development for the mosquito-borne dengue virus has been challenging due to the need to protect equally against all four dengue strains. The discovery of new possible biomarkers to predict clinical and immune responses to dengue virus infection could be critical to informing future vaccines.

The University of Vermont Graduate College has announced that Beth Kirkpatrick, M.D., professor and chair of microbiology and molecular genetics, has been named one or three 2021-2022 University Scholars. The University Scholars program recognizes distinguished UVM faculty members for sustained excellence in research, scholarship, and creative arts.

On March 18, 2021, researchers from across UVM came together via Zoom for the second edition of the Translational Global Infectious Diseases Research Center's COVID-19 research slam, titled “UVM Tackles COVID-19: Research Progress and Perspectives One Year into the Pandemic.”

Sarah Nowak, Ph.D., and David Seward, M.D., Ph.D., were invested as the inaugural holders of a Huber Early Career Green and Gold Professorship of Pathology and Laboratory Medicine during a virtual ceremony March 30. UVM Professor of Pathology and Laboratory Medicine Emerita Sally Huber, Ph.D., established two separate Green and Gold professorships, one in honor of each of her parents, that will provide crucial funding to promising assistant professors who are likely to develop into successful, independent basic scientists or physician-scientists.

The UVM Medical Center and Vaccine Testing Center have successfully reached and surpassed the targeted number of enrollees for an ongoing Phase 3 clinical trial of the AstraZeneca COVID-19 vaccine.

(NOVEMBER 23, 2020) Benjamin Lee, M.D., associate professor of pediatrics, discusses when it is safe to begin opening schools in an interview with WCAX-TV anchor Darren Perron in a segment, titled "What goes into deciding when it’s safe to open schools."

Can schools safely remain open or reopen during periods of significant community spread of COVID-19? According to predictions from a UVM model of SARS-CoV-2 transmission in the school setting, yes – if appropriate precautions are followed both in school and in the community.

An internationally recognized physician-scientist, Beth Kirkpatrick, M.D., has a decades-long history of leadership in the field of vaccine testing and development. In 2001, she launched the UVM Vaccine Testing Center (VTC), and since then, the VTC has grown to assume a prominent role in the development and evaluation of vaccines for globally important infectious diseases. The VTC has garnered support from the National Institutes of Health, the Bill & Melinda Gates Foundation, and the U.S. Department of Defense, among others. Kirkpatrick is also principal investigator and director of UVM’s Translational Global Infectious Disease Research Center of Biomedical Research Excellence and Chair of the Department of Microbiology and Molecular Genetics.

The Larner College of Medicine hosted the fifth annual "Dean's Celebration of Excellence in Research" on November 4 and 5. The two-day event highlighted the research being conducted by junior faculty, senior faculty, postdoctoral trainees, and graduate students at the College.

New research, published in Clinical and Translational Immunology by UVM Associate Professor Sean Diehl, Ph.D., and colleagues provides a clearer picture of the protective antibodies induced by the SARS-C0V-2 virus and their role in serious illness and what’s needed for full protection.

New research, published by scientists at the University of Vermont and Caltech in the journal Cell, has pinpointed three specific mechanisms that allow SARS-CoV-2 to incapacitate human cells by disabling the cell’s alarm system to call for help or warn nearby cells of infection.

A team of scientists at the University of Vermont, working in partnership with a group at the University of Washington, has developed a method of testing for the COVID-19 virus that doesn’t make use of these chemicals but still delivers an accurate result, paving the way for inexpensive, widely available testing in both developing countries and industrialized nations like the United States, where reagent supplies are again in short supply.

In late March, Professor of Surgery Gary An, M.D., and Assistant Professor of Surgery R. Chase Cockrell, Ph.D., joined an international coalition of virologists, pharmacologists, and mathematicians to help build a computer model of SARS-CoV-2 tissue that simulates the changing behavior of the virus once it enters the body.

(MAY 11, 2020) Jason Bates Ph.D., D.Sc.,professor of medicine, and C. Matthew Kinsey, M.D., M.P.H., assistant professor of medicine, are featured in a New Yorker article, titled "The Engineers Taking on the Ventilator Shortage," about a ventilator they invented with College of Engineering and Mathematical Sciences faculty colleagues designed for COVID-19 patients.

University of Vermont scientists, physicians, and students gathered at the Larner College of Medicine February 6 for the first-ever on-campus “virus slam” hosted by the Translational Global Infectious Diseases Research Center. At the event, some twenty experts, from five UVM colleges and institutes, gave five-minute mini-talks that ranged from explaining the biochemistry of the virus’ interaction with the human immune system to interpreting the latest data from the World Health Organization.

Investigators in UVM's Vaccine Testing Center and Center for Translational Global Infectious Disease Research (TGIR) have uncovered details of the human immune response to infection with dengue - a close "cousin" of the Zika virus - which 40 percent of the global population is at risk for contracting. Their study findings were reported recently in the Lancet’s open-access journal EBioMedicine.

Leaders at the University of Vermont and Larner College of Medicine announced $12.3 million in funding for a new Center of Biomedical Research Excellence (COBRE) called the “Translational Global Infectious Disease Research Center” (TGIR) that will join together two traditionally distinct groups of scientists to develop innovative approaches to prevent and control infectious disease.